In silico prediction of mozenavir as a potential drug for SARS-CoV-2 infection via binding multiple drug targets

Since the epidemic began in November 2019, no viable medicine against SARS-CoV-2 has been discovered. The typical medication discovery strategy requires several years of rigorous research and development as well as a significant financial commitment, which is not feasible in the face of the current...

Descripción completa

Detalles Bibliográficos
Autores principales: Mamidala, Estari, Davella, Rakesh, Praveen Kumar, Munipally, Swamy, Satyanarayana, Abhiav, Mruthinti, Ali Kaimkhani, Zahid, Al-Ghanim, K.A., Mahboob, Shahid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522677/
https://www.ncbi.nlm.nih.gov/pubmed/34690521
http://dx.doi.org/10.1016/j.sjbs.2021.10.023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522677/
https://www.ncbi.nlm.nih.gov/pubmed/34690521
http://dx.doi.org/10.1016/j.sjbs.2021.10.023

Ejemplares similares